Skip to content

BIOTECH-INVEST

Active Private limited companyfounded 2002active for 24 yearsBrugstraat 48, 9921 LievegemKBO/BCE: BE 0476.881.001

Lifetime

20 annual accounts with figures on one time axis, 23 filings since 2003
peak of €348,432 in 2025
€348,432▲ 66.3%
peak of €354,979 in 2022
€203,964▲ 127%
peak of €1.7m in 2025
€1.7m▲ 13.2%
€465,277▼ 50.2%
peak of 1 FTE in 2006
-not published
Board2 names since 2018
2 directors and 1 other
Documentsfilings and deeds
30-03-202631 days before the deadline
2025micro format
Gross margin from €209,570 to €348,432Result from €89,998 to €203,964Equity from €1.5m to €1.7mDebts from €934,926 to €465,277

Key points

from the 2025 annual accounts

Equity

€1.7m ▲ 13.2%

BIOTECH-INVEST has made a profit in every financial year since 2006.

Result

€203,964 ▲ 127%
€90,0002024€204,0002025

The result rose in 2025 from €89,998 to €203,964.

Turnover

≈ €680,000 estimated

The accounts state no turnover.

Liquidity

3.28 was 1.86 in 2024

Short-term debts fell from €887,887 to €435,746.

Filings

23 annual accounts since 2003
deadline20102020

The last five annual accounts were filed 2 to 31 days before the end of the period.

Position in the sector

€203,964

Higher net result than 95% of companies in advertising and market research. Sector median €14,082 · 9,133 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as BIOTECH-INVEST has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for BIOTECH-INVEST. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director

Shares in 1 company,

Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0476881001
(director) and (director) change roles General meeting of 01-12-2023 · Gazette deed
appointed as manager General meeting of 01-10-2018 · Gazette deed
Capital increase of €515,700 to €534,300 The capital rose from €18,600 to €534,300, with 644 new shares · General meeting of 25-09-2014 · Gazette deed
All 34 events

Comparable companies

same main activity, similar in size and age
Company
BIOTECH-INVEST Lievegem €2.2m €348,432 79.0% -
LUC PETIT Perwez €2.5m €328,633 95.8% -
RONALD MCDONALD KINDERFONDS - FONDS RONALD MCDONALD POUR LES ENFANTS Jette €2.3m €302,636 37.7% 2.6
BC PARTNERS Oudenaarde €2.5m €260,807 94.0% -
M. VANDERHEYDEN Sint-Martens-Latem €1.8m €284,317 61.0% 0
Mach Media Ghent €2.2m €284,218 72.5% 2
IVAN COPPENS Bruges €1.8m €358,779 92.3% -

These companies have the same main activity as BIOTECH-INVEST: public relations and communication consultancy (NACE 73300). They are comparable in size and age: total assets between €1.8m and €2.5m, founded between 1999 and 2008.

Official details

Source: KBO
Status
Active since 12-02-2002Normal situation
Activity
Public relations and communication consultancyNACE 73300and 1 other
Establishment unit
2.131.506.0119921 Lievegem, since 25-06-2002
Financial year end
30 September
Peppol
Reachable since 28-04-2026
Company details

Annual accounts to 30-09-2025

€2.2m▼ 10.7%
Filing
Filed on 30-03-2026, 31 days before the end of the filing period
Financials

Insights on BIOTECH-INVEST

BIOTECH-INVEST files the micro format. That format states no turnover. The gross margin rose from €138,613 in 2006 to €348,432 in 2025.

The balance sheet grew most from 2020 to 2022 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BIOTECH-INVEST

What is the company number of BIOTECH-INVEST?
The company number of BIOTECH-INVEST is 0476.881.001. The VAT number is the same number with BE in front: BE 0476.881.001.
Where is BIOTECH-INVEST based?
The registered office is at Brugstraat 48, 9921 Lievegem.Company details
What does BIOTECH-INVEST do?
According to the KBO register, the main activity is public relations and communication consultancy (NACE 73300).
What is the legal form of BIOTECH-INVEST?
BIOTECH-INVEST is a private limited company (BV).
When was BIOTECH-INVEST founded?
BIOTECH-INVEST was founded on 12-02-2002.
Is BIOTECH-INVEST still active?
Yes, BIOTECH-INVEST is an active enterprise in the KBO register.
What is the turnover of BIOTECH-INVEST?
The turnover in financial year 2025 is ≈ €680,000. This figure is estimated from the gross margin of €348,432 and 47 comparable companies (NACE 73). It probably lies between €470,000 and €890,000.Financials
Is BIOTECH-INVEST profitable?
In financial year 2025, BIOTECH-INVEST made a profit of €203,964.
Where can I find the annual accounts of BIOTECH-INVEST?
BIOTECH-INVEST filed 23 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BIOTECH-INVEST due?
BIOTECH-INVEST must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.